Dateline City:
WHITEHOUSE STATION, N.J.
By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that in November and December, data will be presented
for the first time investigating the use of KEYTRUDA
(pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma
in comparison to chemotherapy, and in relapsed/refractory classical
Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer
(TNBC).
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more